Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma

Overview of attention for article published in Frontiers in immunology, July 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 8 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 39,355 followers.

RT @FrontImmunol: New Research: Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in…

31 Jul 2023

Reply Repost Favourite

RT @FrontImmunol: New Research: Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in…

31 Jul 2023

Reply Repost Favourite

New Research: Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma: Introduction Classical Hodgkin lymphoma (cHL) is the most… #immunology

31 Jul 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.